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Introduction: Epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors are widely used to treat lung adenocarcinomas with
EGFR-activating mutations. However, half of the patients acquire
resistance because of the gatekeeper T790M mutation. Noninvasive
mutation detection system is desired considering the difficulty in
obtaining tissue specimens during disease progression.
Methods: Sixty-seven plasma DNA samples from 49 patients with
lung adenocarcinoma and 30 healthy volunteers were evaluated.
T790M in plasma DNA was determined using the mutation-biased
polymerase chain reaction (PCR) quenching probe (MBP-QP)
method. The method combines MBP and genotyping, the latter
based on analysis of the melting curve of the probe DNA binding the
target mutated site using a fluorescence QP system.
Results: The detection limit was two copies of control plasmid and 0.2
ng of genomic DNA. The mutant plasmid could be detected when it
accounted for as little as 0.3% of a mixture of plasmids carrying EGFR
exon 20 with or without T790M. The T790M mutation was detected in
plasma DNA from 10 of 19 patients (53%) who acquired resistance, but
not in nonresponders, patients responding to treatment, or those not
treated with EGFR tyrosine kinase inhibitor. Other mutation detection
systems, such as the nucleic acid-locked nucleic acid PCR clamp, the
cycleave PCR technique, and allele-specific oligonucleotide PCR, de-
tected T790M in three, four, and six patients, respectively, among 10 in
which T790M was detected by the MBP-QP method.
Conclusions: The MBP-QP method is simple, sensitive, and—
intriguingly—reflective of clinical course, compared with the other
three mutation-detection systems. Thus, the MBP-QP method is an
ideal noninvasive monitoring system for detecting T790M in plasma
samples.
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Lung cancer is the leading cause of death among malignanttumors worldwide with median survival of only 8 to 10
months in patients with advanced non-small cell carcinoma.1
Although prognosis (overall survival) has improved to 27 to
30.5 months since epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) were introduced for the treat-
ment of patients with lung adenocarcinoma with EGFR-activat-
ing mutations, a crucial unsolved problem is acquired resistance
to EGFR-TKI, which occurs within 9.5 to 14 months.2–5
A second EGFRmutation, substitution of threonine 790
with methionine (T790M), was detected in 50% of tumor
samples with acquired resistance to EGFR-TKI.6–11 This
mutation is in a position analogous to T315I in ABL, T674I in
PDGFRA, and T670I in KIT, mutations that cause resistance
to imatinib. The T315I substitution in ABL blocks imatinib
binding by steric hindrance, but the T790M mutant retains
binding affinity for gefitinib. However, T790M activates the
wild-type EGFR and increases the affinity for ATP in EGFR-
activating mutants resulting in resistance to EGFR-TKI.12,13
Recently, T790M-specific inhibitors have been identified that
are 30- to 100-fold more potent against T790M and up to
100-fold less potent against wild-type EGFR.14 Because the
T790M mutation is not the only cause of acquired resistance
to EGFR-TKI, it is important to determine the type of
resistance in each patient to decide on appropriate treatment.
A monitoring system is indispensable to achieving such a
specific level of treatment. A noninvasive system is necessary
considering the difficulty obtaining cancer specimens during
disease progression, as the majority of recurrences occur in
distant sites such as brain, bone, or intrapulmonary regions.1
To date, two different systems have been reported for
noninvasive detection of T790M: circulating tumor cells
(CTC) and plasma DNA. One of the collecting systems for
CTC is the CellSearch System, a semi-automated system in
which CTC are immunomagnetically captured, with an anti-
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body against an epithelial cell adhesion molecule, and quan-
tified.15–18 However, the prevalence of CTC using this system
was less than 5 cells per 7.5 ml of peripheral blood in patients
with stage IV lung cancer.15 A microfluidic-based device (the
CTC-chip) has been developed to improve yields, but is not
yet available for routine clinical use.16,19 The alternative is
detection by means of plasma DNA. Cell-free circulating
DNA in the plasma of patients with cancer has molecular
characteristics identical to primary tumors.20–25 Because the
population of T790M-positive cancer cells is small, a very
sensitive method, the Scorpion Amplification Refractory Mu-
tation System, has been used for DNA amplification. Al-
though Scorpion Amplification Refractory Mutation System
can detect 54% of patients having T790M among those with
prior clinical response to gefitinib or erlotinib, it requires
whole genome amplification to do so.25 In addition, the
procedure requires complicated molecular techniques.
In this study, we report the development of a novel
method to identify T790M in plasma DNA. The detection
system includes fully automated genotyping, based on anal-
ysis of the probe DNA melting curve, which binds the target
mutated site using a fluorescent guanine quenching probe
(QP-system). Originally, we developed this QP-system for
detecting single-nucleotide polymorphisms, such as
CYP2C19, in genotyping.26 Subsequently, the system was
used to detect a JAK2 tyrosine kinase mutation, a substitution
of valine to phenylalanine at codon 617 (JAK2V617F), in 100
l of blood for diagnosis of chronic myeloproliferative dis-
ease.27 Those applications used cell-based detection systems,
but we have improved the sensitivity to detect the minor
population of T790M EGFR in plasma DNA using the
QP-system combined with mutation-biased polymerase chain
reaction (PCR) (MBP) or MBP-QP. Using the MBP-QP
method, we examined EGFR mutation T790M in plasma
DNA. We discuss its clinical significance in this article.
PATIENTS AND METHODS
Cell Lines and Patient Selection
Human lung cancer cell lines H1975 and A549 were
purchased from the American Type Culture Collection (Manas-
sas, VA). A549 cells were cultured in RPMI-1640 supplemented
with 10% fetal bovine serum at 37°C in 5% CO2. H1975 cells
were cultured in RPMI-1640 containing 10 mM HEPES, 1 mM
sodium pyruvate, 2.5 g/liter glucose, 1.5 g/liter sodium bicar-
bonate, and supplemented with 10% fetal bovine serum. Blood
and lung cancer specimens, including tissue, pleural effusion,
and pericardial effusion, were obtained from 67 plasma samples
from 49 patients with lung adenocarcinoma and 30 healthy
volunteers. Patients with cancer underwent treatment with ge-
fitinib or erlotinib at Saga University Hospital or Saga Prefec-
tural Hospital Koseikan from 2000 to 2009. Table 1 shows
clinical characteristics of these patients. Twenty-six plasma
samples were collected when EGFR-TKI discontinued, and 18
plasma samples were obtained during treatment of EGFR-TKI.
As a control population, 23 patients with lung adenocarcinoma
with EGFR-activating mutations and no history of EGFR-TKIs
treatment were selected during the same period. For the purpose
of T790M monitoring in plasma, these plasma samples were
collected from the same patients one to three times, such as
before, during, and after EGFR-TKI treatment. The clinical
stage of the cancer was determined according to criteria in the
6th edition of the International Union Against Cancer when
plasma samples were collected.28 Blood from healthy volunteers
was obtained at random from staff of the medical department.
The study protocol was approved by the Clinical Research
Ethics Committee of Saga University and Saga Prefectural
Hospital Koseikan. All patients and volunteers gave informed
consent for obtaining blood and tissue specimens according to
the Declaration of Helsinki.
TABLE 1. Characteristics of Patients with Lung Adenocarcinoma
EGFR-TKI Discontinued
(n  26)
EGFR-TKI Continued
(n  18)
EGFR-TKI Untreated
(n  23)
All Patients Examined
(n  49)
Age (yr) 64.5  11.02 68.5  11.64 68  13.89 65  12.41
Sex, n (%)
Male 10 (38.5) 7 (38.9) 12 (52.2) 21 (42.9)
Female 16 (61.5) 11 (61.1) 11 (47.8) 28 (57.1)
Smoking status, n (%)
Smoker 10 (38.5) 9 (50.0) 13 (56.5) 18 (36.7)
Never smoker 16 (61.5) 9 (50.0) 10 (43.5) 31 (63.3)
Stage, n (%)
I 0 0 5 (21.7)
II 0 0 0
III 2 (7.7) 0 4 (17.4)
IV 24 (92.3) 18 (100) 14 (60.9)
EGFR-activating mutation, n (%)
Positive 20 (77.0) 17 (94.4) 23 (100) 42 (85.7)
Wild type 3 (11.5) 1 (5.6) 0 4 (8.2)
NE 3 (11.5) 0 0 3 (6.1)
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; NE, not evaluated.
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DNA Extraction from Lung Cancer Specimens
and Detection of EGFR-Activating Mutations
Genomic DNA was isolated from specimens using
QIAamp DNA mini kits (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. Mutations in exons 18, 19,
and 21 were determined by direct sequencing or the nucleic
acid-locked nucleic acid PCR clamp (PNA-LNA PCR clamp).
Primers for direct sequencing of EGFR have been described
previously.29 The PNA-LNA PCR clamp assays were conducted
by the Mitsubishi Chemical Medience Corporation (Tokyo,
Japan).
DNA Extraction from Plasma and Detection of
the EGFR T790M Mutation
Peripheral blood samples from healthy volunteers and
patients with lung cancer were collected into tubes containing
3.8% citric acid. Plasma was immediately separated from
blood cells by 3000 rpm centrifugation at 4°C for 20 minutes.
Supernatants were collected and stored at80°C until assays
were performed. DNA was isolated from 200 l of patient
plasma using a QIAamp DNA mini kit (Qiagen) according to
the manufacturer’s instructions. DNA concentration was cal-
culated based on absorbance at 260 nm. T790M mutation was
detected using the MBP-QP method described below.
The MBP-QP Method and Preparation of
Control Plasmid
To detect the EGFR T790M mutation in plasma, we
developed the MBP-QP method, a modified QP-system26,27
using i-densy (ARKRAY, Inc., Kyoto, Japan) (Figures 1A, 2).
MBP-QP is a fully automated system with two steps: muta-
tion-biased PCR (MBP) and QP-system analysis. For MBP,
the primers for wild type and mutant were mixed with
genomic DNA, which leads to high specificity because each
primer could be competitively hybridized to wild-type and
mutant sequences. In addition, the length of primer for mutant
FIGURE 1. (A) Principles of the
MBP-QP method. The MBP-QP
method is a modified QP-system
using i-densy and contains two
steps, mutation-biased PCR (MBP)
and a quenching probe (QP)-sys-
tem. In MBP, different primer
lengths for wild-type and mutant
sequences, and the addition of five
bases of random sequence to the
reverse primers, leads to a higher
efficiency of amplification of the
mutant sequence relative to that of
the wild type. Presence of the
T790M sequence is determined by
the QP-system, in which the fluo-
rescence intensity of a TAMRA-con-
jugated-specific guanine quench
fluorophore probe complementary
to T790M is monitored. When a
QProbe is hybridized to target
DNA, its fluorescence is quenched
by the guanine in the target,
which is complementary to the
modified cytosine. After PCR, the
temperature is reduced to 40°C
and then gradually increased. To
identify the wild-type and mutant
amplicons, the fluorescence inten-
sity at the different temperatures is
measured. When the QProbe disso-
ciates from the amplicon, wild type
at 59°C and mutant at 66°C, the
fluorescence intensity increases. (B)
The results of the MBP-QP method
(left) and PCR-based direct se-
quencing (right) of genomic DNA
isolated from H1975 cells are
shown.
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was longer than that for wild type, and annealing temperature
was designed to be optimum to mutant primer, resulting in
higher efficiency of amplification of the mutant than of the
wild-type sequence. PCR conditions were 95°C for 60 sec-
onds and 50 cycles at 95°C for 1 second and 64°C for 15
seconds. The primer sets used were as follows: 5-TCCAG-
GAAGCCTACGTGATGGCCAG-3 for the forward primer
and 5-CTACGCGAAGGGCATGAGCTGCG-3 for the re-
verse primer of the wild-type sequence, and 5-TGCTC-
CCGAAGGGCATGAGCTGCA-3 for the reverse primer of
the mutant sequence. The reverse primers contained five
bases of random sequence at the 5-end (underlined). There-
fore, the specificity of PCR was increased because the se-
quences of each amplified products contained five different
bases. The bold characters indicate the mutated base. The
presence of T790M in the amplified sequences was deter-
mined by monitoring the fluorescence intensity of a TAMRA-
conjugated, specific guanine quench fluorophore probe (QProbe,
J-Bio21, Tokyo, Japan), which is complementary to T790M:
5-TGAGCTGCATGATGAGGTGCAC-(TAMRA)-3. When
the QProbe was hybridized with the target DNA, its fluores-
cence was quenched by the guanine in the target sequence,
which is complementary to the modified cytosine at the
3-end. After PCR was completed, the temperature was re-
duced to 40°C and then gradually increased. Fluorescence
intensity at different temperatures was measured to identify
wild-type and mutant amplicons, because the fluorescence
intensity depends on the QProbe dissociation from the am-
plicon: wild type at 59°C and mutant at 66°C. The control
plasmid was prepared as follows by GenScript USA, Inc. A
300-bp DNA fragment (Accession No. NT_033968 4838290-
4838589) was obtained by PCR, purified, and subcloned into
the pUC57 vector. T790M was also detected by the PNA-
LNA PCR clamp, the cycleave PCR technique, allele-specific
oligonucleotide PCR (ASO-PCR), and direct sequencing. The
PNA-LNA PCR clamp and cycleave PCR techniques were
performed by the Mitsubishi Chemical Medience Corporation
and SRL, Inc. (Tokyo, Japan), respectively. Examinations
using ASO-PCR were performed as described elsewhere.30
Primer sets used were as follows: 5-ACCATGCGAAGC-
CACACTGACG-3 for the forward primer and 5-GC-
CGAAGGGCATGAGCTGGA-3 for the reverse primer. Di-
rect sequencing was performed using the products amplified
by the MBP-QP method. The amplified product was heated to
95°C for 1 minute and isolated using Microcon YM-50
(Millipore, Inc., MA), then sequenced directly using the
Applied Biosystems PRISM dye terminator cycle sequencing
method with ABI PRISM 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA). The MBP forward primer was
used.
RESULTS
MBP-QP Method for Detecting the T790M
EGFR Mutation
We first identified T790M in genomic DNA isolated
from H1975, a lung adenocarcinoma cell line carrying the
T790M mutation, using the MBP-QP method (Figures 1A, 2).
FIGURE 2. Detection of T790M mutation with plasma DNA using the MBP-QP method. (A) The device for the MBP-QP
method. (B) The equipment used for the MBP-QP method. Four microliters of purified DNA is applied to PCR and detection
tube. Reagents, primers, and the specific probes are mixed with the template DNA and reaction is started. The entire process
is performed automatically. MBP-QP, mutation-biased PCR quenching probe.
TABLE 2. Detection of T790M EGFR Mutation Using the
MBP-QP Method
Threshold
Quantity Ratio (%)
Plasmid 2 copies 0.3a
Genomic DNA 0.2 ng 0.4b
a Percentage of control plasmid carrying the T790M EGFR mutation relative to the
amount of wild-type plasmid in the mixture.
b Percentage of genomic DNA isolated from H1975 (T790M) in the mixture with
that from A549 (wild).
EGFR, epidermal growth factor receptor; MBP-QP, mutation-biased PCR quench-
ing probe.
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Direct sequencing confirmed that H1975 cells harbor both a
T790M and a wild-type allele (Figure 1B). Wild-type and
mutant sequences were clearly distinguished because their
melting temperatures (Tm) differ as noted in Patients and
Methods section. Using this system, we examined the detec-
tion limit for T790M. Using a control plasmid containing
EGFR exon 20 with the T790M mutation, or genomic DNA
isolated from H1975, the detection limits were two copies
and 0.2 ng, respectively (Table 2). When two plasmids
carrying EGFR exon 20 with or without the T790M mutation
were mixed in different ratios, the detection limit for T790M
was 0.3% mutant plasmid. Similarly, when genomic DNA
isolated from mixtures of H1975 cells and A549 cells (wild
type) were tested, the detection limit was 0.4% H1975 cells.
T790M Detected in Plasma DNA Only in
Patients Who Experienced Progression During
EGFR-TKI Treatment
Using the MBP-QP method, we examined plasma DNA
of patients with lung adenocarcinoma who acquired resis-
tance to EGFR-TKI treatment to establish a noninvasive
system to detect the presence of T790M mutation. The
criteria for acquired resistance were defined according to
Jackman et al.,31 as follows: previous treatment with a single
EGFR-TKI, a tumor that harbors an EGFR mutation associ-
ated with drug sensitivity or objective clinical benefit from
treatment with an EGFR-TKI, systemic progression of the
disease while on continuous treatment with an EGFR-TKI
within the last 30 days, and no intervening systemic therapy
between cessation of an EGFR-TKI and initiation of new
therapy. According to these criteria, we defined 19 patients
with lung adenocarcinoma who acquired resistance to EGFR-
TKI (Tables 3, 4). Among them, the T790M mutation was
detected in plasma DNA from 53% (10/19; Table 3). The
results of the MBP-QP method are shown in Figure 3. The
TABLE 3. Detection of the T790M EGFR Mutation in
Plasma DNA
Detection
Frequency (%)
Patients with lung cancer treated with EGFR-TKI
(n  44)
CR, PR, SD 3 PD 10/19 (53)a
PR, SD 3 discontinuation by side effect 0/5 (0)
PD 3 PD 0/2 (0)
PR, SD 3 continuing 0/18 (0)
Patients with lung cancer with EGFR-activating
mutations without EGFR-TKI treatment
(n  23)
0/23 (0)
Healthy volunteers (n  30) 0/30 (0)
a The T790M mutation was verified in two cases using tissue samples from
metastatic lesions in the liver and pericardial effusions.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CR,
complete response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 4. Clinical Characteristics and EGFR Mutations in Patients with Lung Adenocarcinoma Whose Tumors Acquired
Resistance to EGFR-TKI
No. Sex
Age
(yr) SIa Stage
EGFR-Activating
Mutation
(Pretreated)
Response to
EGFR-TKI
TTPb
(d) Outcome
T790M
Pretreated Plasma
From PD to
Plasma
Collection (d)
1 F 77 0 IV DEL E746-T751 PR 301 Death   140
2 F 63 0 IV NE PR 232 Death NE  81
3 F 60 0 IV DEL L747-P753 PR 595 Death   336
4 F 65 0 IV NE PR 119 Death NE  7
5 M 71 900 IV L858R PR 43 Death   10
6 F 56 600 IV DEL E746-A750 CR 1084 Death   98
7 F 86 0 IV L858R PR 540 Death NE  1
8 F 66 0 IV DEL E746-A751 SD 209 Alive   31
9 F 79 0 IV DEL L747-T751 PR 217 Alive   29
10 F 62 0 IV Wild type SD 129 Alive   10
11 F 47 100 IV DEL E746-A750 PR 348 Death   449
12 M 64 0 IV Wild type PR 216 Alive   20
13 M 65 800 IIIB L858R SD 133 Death   52
14 F 67 200 IV NE PR 1077 Alive NE  203
15 M 42 200 IV L858R PR 401 Alive   11
16 F 57 0 IV DEL L747-A750 SD 509 Alive   208
17 M 59 240 IV DEL D757-E759 PR 116 Death   0
18 M 63 800 IV L858R SD 212 Alive NE  71
19 F 75 0 IV DEL E746-A750 PR 173 Alive   71
a Smoking index: the number of cigarette-years.
b Time to progression: days from initiation of each EGFR-TKI treatment to progressive disease.
NE, not evaluated; PD, progressive disease; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; SI, smoking index; TTP, time to progression; PR, partial
response; CR, complete response; SD, stable disease.
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T790M mutation was not detected in any patients who re-
mained sensitive to EGFR-TKI treatment or in nonre-
sponders. The clinical characteristics and EGFR mutation
status of the patients who acquired resistance to EGFR-TKI
are listed in Table 4. EGFR-activating mutations were ob-
served in 14 patients, exon 19 was deleted in 9, and the
L858R mutation was found in 5. In patients 6 and 7, the
T790M mutation was also detected in metastatic lesions in
the liver and in a pericardial effusion sampled at the same
time as the plasma DNA. Twenty-three patients with EGFR-
activating mutations who were not treated with EGFR-TKI,
and all of the healthy volunteers were also examined; the
T790M mutation was not detected in plasma from any of
these subjects. As for T790M in cancer tissues before treat-
ment, 32 patients with lung adenocarcinoma among 49 could
be examined; T790M was detected in three patients (9.4%)
using the MBP-QP method. All three patients were among
those who acquired resistance to EGFR-TKI listed in Table 4.
However, T790M was detected in plasma DNA from only
one patient after disease progression.
Monitoring T790M Using the MBP-QP Method
To investigate whether the MBP-QP method can be
adapted for clinical use for monitoring the T790M mutation
using plasma samples, we examined the levels of T790M
mutation during EGFR-TKI treatment. In patient 1, T790M
was not detected in the surgical specimen. Gefitinib treatment
was administered when recurrence was obvious after surgery,
but it was discontinued because of side effects. Plasma DNA
was collected before treatment with erlotinib, and T790M
was not detected. After development of acquired resistance to
erlotinib and gefitinib, T790M was detected in plasma DNA
(Figure 4A). At that time, metastatic lesions rapidly spread to
the lung, pleura, and bilateral adrenal glands. T790M was
also detected 81 days after resistance to gefitinib was ac-
quired in patient 2, but not before gefitinib treatment (Figure
4B). The level of T790M in that patient was greater than in
other positive cases, and multiple metastatic lesions in the
lung, brain, liver, and bilateral adrenal glands were observed.
Plasma DNA was obtained from patient 5 at three time points
FIGURE 3. Results of the MBP-QP method using plasma DNA of patients with lung adenocarcinoma with tumors that devel-
oped resistance to EGFR-TKIs. MBP-QP, mutation-biased PCR quenching probe; EGFR, epidermal growth factor receptor; TKI,
tyrosine kinase inhibitor.
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(Figure 4C). The second collection of plasma DNA, which
was obtained after discontinuation of gefitinib because of side
effects, did not show T790M. However, T790M was detected
in the third collection of plasma DNA when resistance to
erlotinib was acquired and was accompanied by a marked
elevation of carcinoembryonic antigen. In patient 3, whose
primary tumor harbored the T790M mutation, T790M was
not detected during the time when the tumor was responsive
to gefitinib. However, it was clearly detected after resistance
to gefitinib was acquired (Figure 4D). These results suggest
that the MBP-QP system is useful for monitoring T790M
using plasma samples and that a T790M mutation is detected
in plasma DNA when resistance to EGFR-TKI is acquired.
Comparison with Other Methods for Detecting
T790M
T790M detection with the MBP-QP method using plasma
DNA was compared with four other detection systems: PNA-
LNA PCR clamp, the cycleave PCR techniques, ASO-PCR, and
direct sequencing. The MBP-QP method detected T790M in the
plasma DNA of 10 patients, whereas the PNA-LNA PCR clamp
detected T790M in 3 (patients 2, 5, and 9) of those 10 patients.
The cycleave PCR technique detected T790M in four of the
patients (2, 4, 6, and 9). T790M in two patients, 2 and 9, was
detected using all three systems. Thus, 5 of the 10 cases in which
T790M was detected with the MBP-QP method tested negative
for the mutation using either PCR Clamp or Cycleave PCR
(Table 5). To judge which method is most reliable, we also
examined the samples with ASO-PCR, which is extremely labor
intensive, but is the most sensitive method for detecting single-
nucleotide polymorphisms. The detection limit of ASO-PCR
using control plasmid carrying T790M mutation was 50 copies
(data not shown). ASO-PCR detected T790M in 6 of the 10
samples where it was detected by the MBP-QP method. Direct
sequencing was also done using the products amplified by
MBP-QP, with T790M detected in 6 of the 10 cases (Figure 5).
DISCUSSION
We developed a novel, fully automated monitoring
system, MBP-QP, for detecting the EGFR T790M mutation
using plasma DNA. The method is sensitive and can be
FIGURE 4. Representative results
of serial analysis of patients 1 (A), 2
(B), 5 (C), and 3 (D) using the
MBP-QP method to detect the
T790M EGFR mutation in plasma
DNA (plasma) or primary tumor
(primary) of lung adenocarcinomas
from patients whose tumors ac-
quired resistance to EGFR-TKIs.
Patient numbers are the same as in
Table 4. Black and red arrows indi-
cate the peak for T790M mutation
and occurrence of PD, respectively.
EGFR, epidermal growth factor re-
ceptor; TKI, tyrosine kinase inhibi-
tor; chemo, chemotherapy; G, ge-
fitinib, E, erlotinib, CEA,
carcinoembryonic antigen; PD,
progressive disease.
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adapted for monitoring T790M EGFR mutation during treat-
ment with EGFR-TKI. The method is also sensitive to
changes in T790M with progression after an initial response
to EGFR-TKI. Our results suggest that detection of T790M
mutation in plasma DNA is correlated with the development
of acquired resistance to EGFR-TKI, but the presence of the
mutation in primary tumors before treatment with EGFR-TKI
is not predictive of resistance.
The T790M mutation was originally identified in pa-
tients who had relapses after an initial clinical response to
gefitinib,6,7 suggesting that the mutation appeared when drug
resistance developed after treatment with EGFR-TKI. Ac-
cording to recent reports, T790M was detected in 50% of
lung cancer tissues after development of acquired resis-
tance.7–10 In vitro experiments have demonstrated that serial
treatment with gefitinib leads to development of gefitinib
resistance accompanied by the occurrence of the T790M
mutation.32 However, T790M already occurred in the primary
tumors before treatment with EGFR-TKI.33 Subsequently, it
was reported that the T790M mutation exists in a minor
population of cells in the lung cancer before treatment and
that cancer cells with the mutation expand in the population
during progression. In this report, we showed that the T790M
mutation was detected in primary lung cancer tissues of three
lung adenocarcinoma patients, 3, 11, and 12, before treat-
ment. Those patients responded to EGFR-TKI treatment
despite the existence of T790M mutation. One explanation is
that the population of T790M-positive cells was too small to
display resistance. Alternatively, the T790M mutation may
have occurred in one allele of EGFR and the activating
mutation in the other allele. When the T790M EGFR allele
was introduced into lung cancer cell lines in cis with an
activating mutation, the cells developed resistance to EGFR-
TKIs. In contrast, drug resistance was much weaker when the
T790M allele was introduced into cells in trans.32 Determin-
ing how many cells contain the T790M mutation and where
the mutation is located, in cis or trans, relative to EGFR-
activation mutations, may be necessary to clarify the conditions
that promote development of drug resistance to EGFR-TKI. As
for oncogenic activity, the presence of T790M mutation alone
confers a modest increase in EGFR autophosphorylation com-
pared with EGFR-activating mutations. However, double mu-
tants with T790M in cis with either L858R or del746-750
dramatically enhance ligand-independent signaling and trans-
forming activity.34 Although the number of cases in this study
FIGURE 5. The results of direct
sequencing using the products of
the MBP-QP method. MBP-QP,
mutation-biased PCR quenching
probe.
TABLE 5. A Comparison of T790M Detection by MBP-QP
and Other Methods
No MBPa
PCR
Clampb Cycleavec ASO-PCR
MBP 3 Direct
Sequence
1     
2     
3     
4     
5     
6     
7     NE
8     NE
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
a Mutation-biased PCR-QP method.
b Peptide nucleic acid-locked nucleic acid PCR clamp.
c Cycleave PCR technique.
MBP, mutation-biased PCR; QP, quenching probe; PCR, polymerase chain reac-
tion; ASO, allele-specific oligonucleotide; NE, not evaluated.
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was small, the patients in which T790M mutation was detected
in the plasma underwent rapid progression after it was detected.
In this study, there were no differences of progression-free
survival between patients with T790M positive and negative in
plasma DNA (Supplementary Fig. 1A, Supplemental Digital
Content 1, http://links.lww.com/JTO/A117). Overall survival
was tended to be worse in those with T790M positive than
negative, although it was not statistically significant (Sup-
plementary Fig. 1B, Supplemental Digital Content 1,
http://links.lww.com/JTO/A117). However, when T790M
was detected in the primary tumors, but not in the plasma
DNA after progression, the tumor progression was not as
aggressive. Whether the differences were the result of
where the mutated sites occurred, in cis or trans, remains
to be clarified.
Circulating plasma DNA is a good source of predictive
and prognostic markers of lung, colon, and breast can-
cers.20–25 Various genetic and epi-genetic alterations, such as
mutations in p53 and K-ras, microsatellite alterations, and
hypermethylation of tumor suppressor gene promoters, have
been detected in plasma DNA. Because detecting molecular
markers using plasma DNA is noninvasive, it is suitable for
monitoring, but the amount of circulating DNA is small. The
mean concentration of plasma DNA in this study was 190
ng/ml, which is consistent with a previous report.35 There-
fore, a detection system using plasma DNA must be very
sensitive. Our system uses a mutation-biased PCR method,
which enables the mutant sequence to be specifically ampli-
fied using primers of different lengths for mutant and wild-
type sequences (Figure 1A). When combined with the QP-
system, the detection limit was improved from 1.0% in the
QP-system27 to 0.3% in the MBP-QP system, in terms of the
fraction of mutant present among wild type, and T790M was
readily detected using plasma DNA.
To increase specificity, we improved the system in
terms of DNA isolation from plasma and the specific detec-
tion method. Not all circulating DNA is from cancer cells;
circulating DNA is thought to originate from apoptotic and
necrotic tumor cells as well as from apoptotic normal cells,
especially lymphocytes.36 Because the length of DNA differs
between apoptotic cells and normal or tumor cells, or necrotic
cells versus tumor cells, Alu sequences, which are classified
as short interspersed elements and are the most abundant
repetitive DNA elements, were used for estimation of DNA
integrity.37 Kuang et al.25 reported that the ratio of Alu247 to
Alu115 sequences reflected the percentage of tumor cells.
According to their results, the Qiagen method is suitable for
isolation of circulating DNA from plasma, so we used it in
the present investigation.25 The QP-system enabled us to
distinguish mutant from wild-type sequences using a T790M-
specific guanine quenching probe, because the melting tem-
peratures of the mutant and wild-type sequences differ. Con-
sidering the rationale for this system, false positives could
theoretically be prevented. Indeed, we did not detect T790M
in plasma from any healthy volunteers. Moreover, in all
patients with T790M, the sequence was detected 0 to 449
days after development of acquired resistance, consistent
with other reports (Tables 3, 4).6–12 In addition, the T790M
mutation can be detected in less than 10 ng of plasma DNA,
and the detection procedure is fully automated. Compared
with the currently available methods, such as the PNA-LNA
clamp and Cycleave methods, the MBP-QP method is more
sensitive, as judged by ASO-PCR. T790M mutation was
detected in patients with the MBP-QP method, but not with
ASO-PCR. Considering the difference in detection limits—2
versus 50 copies—the result is convincing. Thus, the
MBP-QP method is a sensitive, easy, specific, and noninva-
sive system that can use plasma DNA to detect T790M. There
are two limitations to this study. First, the number of patients
examined was small. Second, it has not been confirmed
whether the result using plasma DNA is consistent with that
using cancer tissues, given that cancer tissue may be consid-
ered the best material for identifying mutations arising in
cancer cells.
EGFR-TKIs have altered not only the prognosis of
patients with lung adenocarcinoma but also the process of
determining an appropriate cancer treatment strategy accord-
ing to the presence or absence of a particular molecular
marker. Molecular markers will become indispensable for
predicting tumor responses and resistance. Acquired resis-
tance needs to be monitored before and during treatment, and
the monitoring system should be noninvasive, sensitive, and
easy to use. Considering these requirements, our novel mon-
itoring system, the MBP-QP method, should be a useful tool
for assessing treatment of patients with lung cancer. This
method uses plasma DNA as an alternative when tissues
samples are not available. The next step will be a prospective
study with strict protocol to validate the validity of the
MBP-QP method.
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